de force and provides an overview on the role of IL-34 in Treg and in tolerance.This work raises several questions. The first one concerns the redundancy and complementarity with its 'twin' cytokine, CSF-1. This complementarity is illustrated here by the increased circulating levels of CSF-1 in IL-34deficient rats. 3 CSF-1 and IL-34 share a common receptor, CSF1R (CD115). However, IL-34 has two additional receptors that do not bind CSF-1. This allows IL-34 to target more cell subsets than CSF-1. In addition to CSF1R, IL-34 interacts with syndecan-1 (CD138) and PTP-ζ, a cell surface proteoglycan. 4 CD138 is expressed by plasma cells, the antibody (Ab)-secreting cells. As stated by the authors, it remains to be determined whether the absence of interactions between IL-34 and plasma cell CD138 in IL-34-deficient rats may explain the presence of multiple auto-Abs in these rats. Nevertheless, the phenotype of IL-34-deficient animals, like CSF-1-deficient mice, is less severe than CSF1R-deficient mice. 7 Besides the mild liver injury and the presence of multiple auto-Abs, IL-34-deficient rats demonstrate a normal appearance with normal growth and bone mass, 3 as previously reported in IL-34-deficient mice. 8 This contrasts with osteopetrosis and severe reduced femur length observed in CSF1Rdeficient mice. 7 These abnormalities reflect the impact of CSFR-1 signalling on osteoclasts. These cells correspond to tissue-resident macrophages (TRMs) of the bones. They are involved in bone resorption and are reduced in CSF1Rdeficient mice. 7 CSF1R signalling is critical for TRM